Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 24% Improvement Relative Risk Progression -7% Case -11% Aspirin for COVID-19  Son et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? PSM retrospective 11,475 patients in South Korea Lower mortality with aspirin (not stat. sig., p=0.52) c19early.org Son et al., Medicine, July 2021 Favors aspirin Favors control

Effect of aspirin on coronavirus disease 2019

Son et al., Medicine, doi:10.1097/MD.0000000000026670
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
19th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.00014 from 72 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
PSM retrospective case control study in South Korea, showing a trend towards lower mortality, but no significant differences with aspirin use.
risk of death, 24.0% lower, OR 0.76, p = 0.52, treatment 37 of 128 (28.9%) cases, 31 of 128 (24.2%) controls, adjusted per study, case control OR, group 1, model 2 (most data in group and adjustments), multivariable.
risk of progression, 7.0% higher, OR 1.07, p = 0.80, treatment 77 of 339 (22.7%) cases, 58 of 339 (17.1%) controls, adjusted per study, case control OR, complications, group 1, model 2 (most data in group and adjustments), multivariable.
risk of case, 11.0% higher, OR 1.11, p = 0.21, treatment 313 of 3,825 (8.2%) cases, 617 of 7,650 (8.1%) controls, adjusted per study, case control OR, group 1, PSM 1, model 2 (most data in group and adjustments), multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Son et al., 30 Jul 2021, retrospective, propensity score matching, South Korea, peer-reviewed, 6 authors.
This PaperAspirinAll
Effect of aspirin on coronavirus disease 2019
MD a , Minkook Son, MD a , Je Myung-Giun Noh, Jeong Hoon Lee, MD c Jeongkuk Seo, MD, PhD Hansoo Park, PhD Sung Yang
Medicine, doi:10.1097/md.0000000000026670
Several studies reported that aspirin can potentially help prevent infection and serious complications of coronavirus disease (COVID-19), but no study has elucidated a definitive association between aspirin and COVID-19. This study aims to investigate the association between aspirin and COVID-19. This case-control study used demographic, clinical, and health screening laboratory test data collected from the National Health Insurance Service database. Patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection until June 4, 2020, were matched with control patients using propensity score matching according to their SARS-CoV-2 status, the composite of complications, and death. The composite of complications included intensive care unit admission, use of vasopressors, high-flow oxygen therapy, renal replacement therapy, extracorporeal membrane oxygenation, and death. Exposure to aspirin was defined as having a prescription for aspirin for more than 14 days, including the index date. After matching, multivariableadjusted conditional logistic regression analysis was performed. To confirm the robustness of this study, we used 2 study groups, 3 propensity score matching methods, and 3 models for conditional logistic regression analyses. The crude odds ratio and 95% confidence interval for SARS-CoV-2 infection between the groups without and with exposure to aspirin were 1.21 (1.04-1.41), but the adjusted odds ratios (95% confidence interval) were not significant. There was no association between aspirin exposure and COVID-19 status. Multiple statistical analyses, including subgroup analysis, revealed consistent results. Furthermore, the results of analysis for complications and death were not significant. Aspirin exposure was not associated with COVID-19-related complications and mortality in COVID-19 patients. In this nationwide population-based case-control study, aspirin use was not associated with SARS-CoV-2 infection or related complications. With several ongoing randomized controlled trials of aspirin in COVID-19 patients, more studies would be able to confirm the effectiveness of aspirin in COVID-19.
Author contributions
References
Alhazzani, Møller, Arabi, Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19), Intensive Care Med
Aly, Ibrahim, Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?, Med Hypotheses
Austin, An Introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res
Bianconi, Violi, Fallarino, Pignatelli, Sahebkar et al., Is Acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19 ?, Drugs
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19, Anesth Analg
Coulombe, Jaworska, Verway, Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages, Immunity
Day, Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists, BMJ
Dotolo, Marabotti, Facchiano, Tagliaferri, A review on drug repurposing applicable to COVID-19, Brief Bioinform
Eisen, Leder, Woods, Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, doubleblind, placebo-controlled primary prevention trial, Lancet Respir Med
Evangelista, Manarini, Dell'elba, Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation, Thromb Haemost
Giannis, Ziogas, Gianni, Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past, J Clin Virol
Glatthaar-Saalmüller, Mair, Saalmüller, Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study, Influenza Other Respir Viruses
Gupta, Madhavan, Sehgal, Extrapulmonary manifestations of COVID-19, Nat Med
Harbi, Tamim, Al-Dorzi, Sadat, Arabi, Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study, BMC Pharmacol Toxicol
Hong, Lee, Kim, Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea, Ann Lab Med
Hsu, Donnelly, Chaudhary, Aspirin use and long-term rates of sepsis:a population-based cohort study, PLoS One
Jeong, Lee, Shin, Choe, Filion et al., Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: a nationwide study, Clin Infect Dis
Jung, Choi, You, Kim, Association of renin-angiotensinaldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study, Clin Infect Dis
Kwon, Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage, Health Policy Plan
Levey, Bosch, Lewis, Greene, Rogers et al., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group, Ann Intern Med
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Morris, Stables, Hobbs, Effects of low-dose aspirin on acute inflammatory responses in humans, J Immunol
Pamukcu, Inflammation and thrombosis in patients with COVID-19: a prothrombotic and inflammatory disease caused by SARS coronavirus-2, Anatol J Cardiol
Park, Choi, Ko, Information technology-based tracing strategy in response to COVID-19 in South Korea-Privacy Controversies, JAMA
Quan, Sundararajan, Halfon, Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, Med Care
Rajasagi, Bhela, Varanasi, Rouse, Frontline Science: Aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology, J Leukoc Biol
Shim, Tariq, Choi, Lee, Chowell, Transmission potential and severity of COVID-19 in South Korea, Int J Infect Dis
Singh, Parida, Lingaraju, Kesavan, Kumar et al., Drug repurposing approach to fight COVID-19, Pharmacol Rep
Son, Seo, Yang, Association between renin-angiotensinaldosterone system inhibitors and COVID-19 infection in South Korea, Hypertension
Song, Jung, Song, Background and data configuration process of a nationwide population-based study using the korean national health insurance system, Diabetes Metab J
Sultana, Crisafulli, Gabbay, Lynn, Shakir et al., Challenges for drug repurposing in the COVID-19 pandemic era, Front Pharmacol
Terpos, Ntanasis-Stathopoulos, Elalamy, Hematological findings and complications of COVID-19, Am J Hematol
Voiriot, Chalumeau, Messika, Risks associated with the use of non-steroidal anti-inflammatory drugs during pneumonia, Rev Mal Respir
Warner, Nylander, Whatling, Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy, Br J Clin Pharmacol
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA
Wiewel, De Stoppelaar, Van Vught, Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host response biomarkers during sepsis: a propensity-matched analysis, Intensive Care Med
Yin, Yamamoto, Gaynor, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta, Nature
Yuan, Chen, Li, Chen, Wang et al., Mortality and prehospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease, J Cell Mol Med
Zhang, Kim, Lonjon, Zhu, written on behalf of AMEB-DCTCGBalance diagnostics after propensity score matching, Ann Transl Med
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit